Cagrilintide & Semaglutide Blend — Dual Amylin + GLP-1 Weight-Management Blend (“CagriSema”)
This fixed-combination blend pairs Cagrilintide, a long-acting amylin analogue, with Semaglutide, a GLP-1 receptor agonist — the investigational combination known as “CagriSema.” It is one of the most studied dual-hormone approaches in obesity and metabolic research (Novo Nordisk REDEFINE program).
Mechanism of Action
The two components act on distinct but converging satiety pathways. Cagrilintide agonizes amylin/calcitonin receptors (calcitonin receptor with RAMP modification), engaging hindbrain satiety signaling and slowing gastric emptying, while Semaglutide activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite centrally. In combination they are studied for additive appetite suppression and greater weight reduction than either component alone.
Available Formats
- 5mg
- 10mg
- 20mg
Reconstitution: Reconstitute with Bacteriostatic Water (BAC Water) for multi-use stability, or Sterile Water for single-use protocols. Store lyophilized vials refrigerated at 2–8°C, protected from light.
Key Research Areas
⚡ Obesity & Weight Management
Combined amylin + GLP-1 satiety is studied for superior weight loss versus monotherapy.
⚡ Type 2 Diabetes / Glycemic Control
GLP-1-driven insulinotropic effect plus amylin glucose modulation.
⚡ Appetite & Satiety Signaling
Dual-hormone control of energy intake through independent receptor systems.
⚡ Cardiometabolic Research
Downstream metabolic effects of substantial weight reduction.
FOR RESEARCH USE ONLY (RUO). This product is not a drug, food, or cosmetic and is not approved for human or veterinary use. All statements describe proposed or preclinical research findings only. Intended strictly for in vitro and laboratory research by qualified professionals. EhBuddy Peptides assumes no liability for misuse.















Reviews
There are no reviews yet.